1.98
-9.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CytomX Therapeutics
From its filings with the US Securities and Exchange Commission
CytomX Therapeutics is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CTMX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $76.2m and a net loss of $17.4m. At that date it held total assets of $151.6m and shareholders' equity of $99.0m.
We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform. This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases. Our masking strategy is designed to reduce binding of biologic therapeutics to their targets until the mask is removed by proteases in the tumor microenvironment, providing more selective targeting of the tumor and optimizing the predicted therapeutic index of our clinical candidates.
CytomX’s two current clinical programs, varsetatug masetecan (“Varseta-M”) and CX-801 are in Phase 1 clinical development and are examples of our focused program development strategy. We aim to continue to advance our clinical pipeline towards later stage development and ultimately build a commercial enterprise to maximize our impact on the treatment of cancer.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Oct 2015
- Employees
- 69
- Website
- cytomx.com ↗
- Head office
- 151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Sean MccarthyChairman of the Board, Chief Executive Officer, since 2011$1.8m
- Mr. Christopher OgdenSenior Vice President, Chief Financial Officer, Assistant Secretary$914,279
- Dr. Yu-Waye ChuSenior Vice President, Chief Medical Officer$808,354
- Mr. Matthew YoungLead Independent Director$138,732
- Dr. Alan AshworthIndependent Director$102,732
- Ms. Halley GilbertIndependent Director$114,232
- Dr. Elaine JonesIndependent Director$108,732
- Mr. James MeyersIndependent Director$110,732
- Dr. Mani MohindruIndependent Director$112,232
- Dr. Zhen SuIndependent Director$210,594
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 62
- Social
- 57
- Governance
- 52
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CytomX Therapeutics employs 69 employees in South San Francisco for oncology-focused biopharmaceutical development.
- CytomX's Probody technology platform enables conditional activation of antibody-based drugs in tumor microenvironments.
- CytomX's clinical pipeline includes CX-2029, CX-904, CX-2051, CX-801, and BMS-986288 for cancer treatment.
Weaknesses
- CytomX has 69 employees, which is fewer than typical biotech companies with similar pipelines.
- CytomX's clinical pipeline lacks detailed information on specific cancer types for each candidate.
- CytomX's IPO date of 8 October 2015 indicates a relatively recent market entry.
Opportunities
- CytomX's Probody technology platform offers potential for new cancer treatments in the Health Care sector.
- CytomX's CX-2029 targets squamous non-small cell lung cancer, a significant market segment.
- CytomX's pipeline includes multiple treatment modalities such as antibody-drug conjugates and T-cell engaging bispecific antibodies.
Threats
- CytomX faces competition from other biotech companies in the Health Care sector.
- CytomX's clinical pipeline requires further development before market approval.
- CytomX's small employee count of 69 may limit its ability to scale rapidly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.